Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + XELOX in HER2-negative, low PD-L1 gastric/GEJ adenocarcinoma (SEARCH)
ChiCTR2500106716Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Qilu Hospital of Shandong University. Primary endpoint: Progression-free survival. Started Jul 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500106716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106716.